Full metadata record
DC FieldValueLanguage
dc.creatorPeen, U. (Ulla)-
dc.creatorGraybill, W. (Whitney)-
dc.creatorGonzález-Martín, A. (Antonio)-
dc.creatorOmalley, D. (David)-
dc.creatorBaurain, J.F. (J. F.)-
dc.creatorPrendergast, E. (Emily)-
dc.creatorFollana, P. (Philippe)-
dc.creatorBraicu, E.I. (Elena Ioana)-
dc.creatorGupta, D. (Dyvia)-
dc.creatorMonk, B.J. (Bradley J.)-
dc.date.accessioned2023-11-21T14:03:05Z-
dc.date.available2023-11-21T14:03:05Z-
dc.date.issued2020-
dc.identifier.citationPeen, U. (Ulla); Graybill, W. (Whitney); González-Martín, A. (Antonio); et al. "Efficacy of individualised starting dose (isd) and fixed starting dose (fsd) of niraparib per investigator assessment (ia) in newly diagnosed advanced ovarian cancer (oc) patients". International journal of gynecological cancer. 30 (Suppl 4), 2020, A1 - A142es_ES
dc.identifier.issn1048-891X-
dc.identifier.urihttps://hdl.handle.net/10171/67945-
dc.description.abstractNiraparib is a poly(ADP-ribose) polymerase inhibitor approved for maintenance treatment of patients with newly diagnosed or recurrent OC that responded to platinumbased chemotherapy and treatment in heavily-pretreated recurrent OC. Here we report efficacy in patients receiving the FSD and ISD in the PRIMA/ENGOT-OV26/GOG-3012 trial (NCT02655016).es_ES
dc.description.sponsorshipFunded by: GlaxoSmithKlinees_ES
dc.language.isoenges_ES
dc.publisherBMJes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectNiraparibes_ES
dc.subjectPolymerase inhibitores_ES
dc.subjectMaintenance treatmentes_ES
dc.subjectPlatinumbased chemotherapyes_ES
dc.titleEfficacy of individualised starting dose (isd) and fixed starting dose (fsd) of niraparib per investigator assessment (ia) in newly diagnosed advanced ovarian cancer (oc) patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.es_ES
dc.identifier.doi10.1136/ijgc-2020-ESGO.154-
dadun.citation.endingPageA142es_ES
dadun.citation.numberSuppl 4es_ES
dadun.citation.publicationNameInternational journal of gynecological canceres_ES
dadun.citation.startingPageA1es_ES
dadun.citation.volume30es_ES

Files in This Item:
Thumbnail
File
A90.2.full.pdf
Description
Size
141.29 kB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.